Year: 2022

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Nov. 14, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended September 30, 2022. “I am proud of the rigorous analysis done by our team over the past six months, and...

Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

— Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six months for the LUM-201 Dose of 1.6 mg/kg/day in the OraGrowtH210 Trial which Supports Advanced Planning for Pivotal Phase 3 Trial — — OraGrowtH210 Trial is ~80% enrolled and Primary Outcome Readout with all 80 Subjects at six months Anticipated 2H 2023 – — First Subject Dosed and Enrollment Ongoing in Massachusetts General Investigator-Initiated Trial evaluating LUM-201 in Non-Alcohol Fatty Liver Disease (NAFLD) — — Cash of $73.7 Million at End of Q3 2022 Provides Runway into Second Quarter 2024 — AUSTIN, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage...

ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

WINSTON-SALEM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments. “During the third quarter of 2022, we made significant advancement in our mission to improve the lives and outcomes for people with CKD. In July, ProKidney listed on the Nasdaq exchange and raised capital that optimally positions us to meet our anticipated clinical milestones. This capitalization moves us closer to bringing REACT® to patients in need as we report data from ongoing studies of REACT, advance additional studies, and launch our second global Phase 3 study, proact 2...

Kering: Disclosure of transactions in own shares – November 7 to 11, 2022

Written by Customer Service on November 14, 2022. Posted in Public Companies.

Paris, November 14, 2022, Disclosure of Transactions in Own Shares In accordance with the authorization given by the shareholders’ annual meeting on April 28, 2022 to trade on its own shares and pursuant to applicable law on share repurchase, Kering (LEI: 549300VGEJKB7SVUZR78) declares the following purchases of its own shares (FR0000121485) from November 7 to 11, 2022: Issuer’s name Issuer’s identifying code Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares Market (MIC code)KERING 549300VGEJKB7SVUZR78 07/11/2022 FR0000121485 9,553 506.4298 XPARKERING 549300VGEJKB7SVUZR78 07/11/2022 FR0000121485 2,147 506.8335 CEUXKERING 549300VGEJKB7SVUZR78 07/11/2022 FR0000121485...

Final terms for bonds to be listed 17th November 2022

Written by Customer Service on November 14, 2022. Posted in Public Companies.

To Nasdaq Copenhagen A/S 14th November 2022 Announcement no. 130/2022 Final terms for bonds to be listed 17thNovember 2022 On 17th November 2022, Jyske Realkredit A/S will be listing new covered bonds (SDO). Final terms for the bonds are attached to this announcement. The full prospectus for the Bond consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated February 22nd, 2022. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely,Jyske Realkredit A/S www.jyskerealkredit.com Please...

70% of Small Businesses Surveyed Globally Want Telecom Providers to Provide Secure Traffic

Written by Customer Service on November 14, 2022. Posted in Public Companies.

73% of small businesses want security to be a core offering of their Internet/data provider Hod Hasharon, Israel, Nov. 14, 2022 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT) (TASE: ALLT), a leading global provider of innovative network intelligence and security-as-a-service (SECaaS) solutions for communication service providers (CSPs) and enterprises, today announced the publication of the results of a survey conducted by Coleman Parkes Research to measure the attitudes of small businesses toward cybersecurity. Among the results of the survey of 1,000 businesses, with 50 employees or less, in North America, Europe and APAC, the following findings were revealed: 70% of small businesses share the view that “It is the responsibility of the Internet provider/CSP to provide secure traffic” 73% of small businesses want security...

Antimicrobial Coatings Market Size to Hit $7.0 billion by 2027 Globally, at a CAGR of 10.8%, says MarketsandMarkets™

Written by Customer Service on November 14, 2022. Posted in Dividend Reports And Estimates.

Chicago, Nov. 14, 2022 (GLOBE NEWSWIRE) — The global Antimicrobial Coatings Market size is estimated to be USD 4.2 billion in 2022 and is projected to reach USD 7.0 billion by 2027, at a CAGR of 10.8%, as per the recent study by MarketsandMarkets™. Growing expenditure on healthcare infrastructure, increase in government initiative to prevent the spread of COVID-19, hospital-acquired infections (HAIs) and increasing demand for medical devices, surgical instruments, and other healthcare equipment across the globe are fuelling the growth of the antimicrobial coatings market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1297 Browse In-Depth TOC On “Antimicrobial Coatings Market” 194 – Market Data Tables 38 – Figures 215 – Pages List of Key Players in Antimicrobial...

Cosmetic Surgery Market Size (2021-2028) Worth USD 58.78 Billion, 3.6% CAGR

Written by Customer Service on November 14, 2022. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, the global Cosmetic Surgery Market Size is projected to reach USD 58.78 billion in 2028, at a CAGR of 3.6% during the forecast period, 2021-2028 Pune, India, Nov. 14, 2022 (GLOBE NEWSWIRE) — The global Cosmetic Surgery Market size was accounted at USD 44.55 billion in 2020. The market is projected to grow from USD 46.02 billion in 2021 to USD 58.78 billion by 2028 while exhibiting a CAGR of 3.9% between 2021 and 2028. This information is published by Fortune Business Insights in its report, titled “Cosmetic Surgery Market Size, Share & COVID-19 Impact Analysis, By Procedure, By Application, By End-User, and Regional Forecast, 2021-2028.” Industry Development:May 2020 – AbbVie Inc. Inc., completed the acquisition of Allergan to strengthen its position as a strong leader in many...

With 28.1% CAGR, Hair Transplant Market Size to Surpass Around USD 43.13 Billion by 2026

Written by Customer Service on November 14, 2022. Posted in Mergers And Acquisitions.

According to Fortune Business Insights, Hair Transplant Market to Reach USD 43.13 Billion by 2026; Positively Impacted by Increasing Development of Advanced Surgical Techniques Pune, India, Nov. 14, 2022 (GLOBE NEWSWIRE) — The global hair transplant market is likely to gain impetus from the ever-increasing number of surgeries performed in males for treating androgenic alopecia. The International Society of Hair Restoration Surgery (ISHRS) mentioned that hair restoration procedures surged by approximately 60% worldwide since 2014 because of the rising cases of alopecia. Fortune Business Insights™ published this information in a recent report, titled, “Hair Transplant Market Size, Share & Industry Analysis, By Type (Surgical and Non-surgical), By Gender (Male and Female) By End User (Hospitals & Clinics and Hair...

Concrete Blocks and Bricks Market Size, Revenue Analysis & Outlook (2022-2029) | Fortune Business Insights™

Written by Customer Service on November 14, 2022. Posted in Mergers And Acquisitions.

Companies covered in concrete blocks and bricks market are CRH plc, Boral Limited, UltraTech Cement Ltd., Cemex S.A.B. de C.V, LCC Siporex Company, Midwest Block and Brick, Magicrete Building Solutions Pvt. Ltd., Monaprecast, Midland Concrete Products, Inc, Brickworks Limited, General Shale, Inc., Oldcastle, Xella Group, Acme Brick Company & more. Pune, India, Nov. 14, 2022 (GLOBE NEWSWIRE) — The global concrete blocks and bricks market size will spike during the forecast period owing to the rising frequency of natural disasters. Fortune Business Insights™ shares this information in its report titled “Concrete Blocks and Bricks Market, 2022-2029.” Natural disasters, such as earthquakes and floods, have been growing in frequency and intensity over the past few decades. According to the Munich Reinsurance...

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals